F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Summary

This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.

Conditions

• Estrogen Receptor Positive
• Recurrent Breast Carcinoma
• Stage IV Breast Cancer AJCC v6 and v7

Interventions

PROCEDURE

Computed Tomography

Undergo F-18 FES PET/CT

PROCEDURE

Computed Tomography

Undergo FDG PET/CT

DRUG

F-18 16 Alpha-Fluoroestradiol

Undergo F-18 FES PET/CT

DRUG

Fludeoxyglucose F-18

Undergo FDG PET/CT

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo F-18 FES PET/CT

PROCEDURE

Positron Emission Tomography

Undergo FDG PET/CT

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• University of Washington

  lead OTHER

Principal Investigators

• Hannah Linden · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-09-15

Primary Completion

2018-12-27

Completion

2021-01-13

FDA Drug

Yes

Countries

• United States

Study Locations